Consensus ARS Pharmaceuticals, Inc.

Stocks

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-08 EDT			5-day change	1st Jan Change
5.390 ^USD	-4.09%		-10.17%	-53.73%

08-13	ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises	MT
08-13	ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026

Evolution of the Average Target: ARS Pharmaceuticals, Inc.

Evolution of the Target Price: ARS Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ARS Pharmaceuticals, Inc.

2983a606.51cZJ5keBz64k_P3FxT093B_r1aS9U2PLs7BheJB-Gk.3iVhbM5zbkjep5fDXHC_z0kt7jrqozjARYet9rcgqRqCPFZ13S1Tf_Smxw~38a80cb2b0dbc763f8cc12eb15001158

Analysts' recommendations: ARS Pharmaceuticals, Inc.

25-09-04	Roth Capital Initiates ARS Pharmaceuticals at Buy With $40 Price Target	MT
25-02-10	Oppenheimer Initiates ARS Pharmaceuticals at Outperform	MT
24-08-20	Cantor Fitzgerald Initiates ARS Pharmaceuticals at Overweight With $30 Price Target	MT
24-08-13	Raymond James Upgrades ARS Pharmaceuticals to Strong Buy From Outperform, Adjusts Price Target to $22 From $18	MT
24-07-25	Raymond James Starts ARS Pharmaceuticals With Outperform Rating	MT
24-03-05	Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6	MT
24-02-20	William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform	MT
24-02-06	Wedbush Raises ARS Pharmaceuticals' PT to $19 From $13 After Model Adjustments, Keeps Outperform Rating	MT
23-11-13	Wedbush Raises ARS Pharmaceuticals' PT to $13 From $5, Says Market Opportunity Intact; Maintains Outperform Rating	MT
23-09-20	William Blair Downgrades ARS Pharmaceuticals to Market Perform From Outperform	MT
23-06-21	Wedbush Trims ARS Pharmaceuticals' PT to $15 From $17, Adjusts US, EU Launch Estimates, Lowers Peak Penetration for neffy/Anaphylaxis in US; Keeps Outperform Rating	MT
23-01-31	Wedbush Initiates ARS Pharmaceuticals at Outperform With $10 PT, Says Neffy Intranasal Spray Set to Shake Up Epinephrine Market	MT
23-01-04	William Blair Initiates ARS Pharmaceuticals With Outperform	MT
22-12-13	SVB Securities Initiates ARS Pharmaceuticals With Outperform Rating, Price Target is $14	MT
22-05-16	Stifel Adjusts Price Target on Silverback Therapeutics to $5 From $6, Reiterates Hold Rating	MT
22-04-04	Goldman Sachs Downgrades Silverback Therapeutics to Neutral From Buy, Adjusts Price Target to $3.50 From $25	MT
22-04-01	JonesTrading Downgrades Silverback Therapeutics to Hold From Buy	MT
22-04-01	SVB Leerink Downgrades Silverback Therapeutics to Market Perform from Outperform, Adjusts Price Target to $1.80 from $25	MT
22-04-01	HC Wainwright Downgrades Silverback Therapeutics to Neutral from Buy	MT
22-04-01	Stifel Downgrades Silverback Therapeutics to Hold from Buy, Adjusts Price Target to $6 from $32	MT
21-11-12	SVB Leerink Adjusts Silverback Therapeutics' Price Target to $25 From $42, Keeps Outperform Rating	MT
21-08-16	Silverback Therapeutics : SVB Leerink Adjusts Silverback Therapeutics' Price Target to $49 from $46, Keeps Outperform Rating	MT
21-05-27	Silverback Therapeutics : JonesTrading Starts Silverback Therapeutics at Buy With $50 Price Target	MT
21-05-24	Silverback Therapeutics : SVB Leerink Adjusts Price Target on Silverback Therapeutics to $46 From $49, Maintains Outperform Rating	MT
21-04-06	Silverback Therapeutics : SVB Leerink Adjusts Price Target on Silverback Therapeutics to $49 From $40, Maintains Outperform Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARS PHARMACEUTICALS, INC.					+313.7%
	LONZA GROUP AG					+22.76%
	REVOLUTION MEDICINES, INC.					+19.26%
	IQVIA HOLDINGS INC.					+3.18%
	BEONE MEDICINES AG					+20.63%
	CELLTRION, INC.					+43.98%
	ASCENDIS PHARMA A/S					+16.3%
	MEDPACE HOLDINGS, INC.					-1.6%
	EUROFINS SCIENTIFIC SE					+1.3%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-2.6%
	Average					+43.69%
	Weighted average by Cap.					+17.60%